A new study by JAMA Health Forum found that universal annual depression screening for young adults during primary care visits is cost-effective and can result in greater benefits if paired with better treatment access and lower costs, particularly for multiracial and Hispanic females.
Cost is a barrier to care for chronic and rare diseases, so financial assistance is way to lower that barrier and help people manage their health condition, says Green, president of Accessia Health
Digital pharmacy solutions can help brick and mortar locations become more efficient, according to Sarah Thomas, VP of sales and commercialization at HealthDyne and David Skomo, COO of HealthDyne.
Cigna is raising its full-year 2025 outlook, with a consolidated adjusted income from operations to be about $29.60 per share.
Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.
A growing and more diverse pipeline means that there is a greater need for digital innovations, which can address affordability, access and industry collaboration, according to Sarah Thomas, VP of sales and commercialization at HealthDyne and David Skomo, COO of HealthDyne.
During the first quarter of 2025, CVS Health recorded a premium deficiency reserve of $448 million within its individual exchange business.
The victims of intimate partner violence were found to have more menopause symptoms, according to the results of a Turkish study published this month in Menopause.
At the 2025 Asembia Specialty Pharmacy Summit in Las Vegas, John Beardsley, senior vice president of corporate business development at CoverMyMeds, and Fauzea Husain, vice president of public policy at McKesson, discussed the future of Medicare drug pricing, including potential changes to the “pill penalty” and efforts to improve transparency in the negotiation process.
Kathi Henson, senior vice president of patient services, nursing and quality at Orsini, spoke with MHE editors at this year’s Asembia Specialty Pharmacy Summit in Las Vegas about how analytics and AI are shaping the future of specialty pharmacy. She highlighted the unique role data plays in improving patient outcomes, managing rising costs and maintaining high standards of care in an increasingly complex field.
Fran Gregory, PharmD, MBA, VP of emerging therapies at Cardinal Health, talks about the importance of market access strategies in the cell and gene therapy space.
Joe DePinto from McKesson discussed the challenges facing cell and gene therapies, particularly around reimbursement, and highlighted successful strategies to speed up access. He also shared optimism for the future, with many products already achieving blockbuster status and more expected by 2030.
Joe DePinto, MBA, head of cell, gene and advanced therapies at McKesson , met with MHE at the annual Asembia Specialty Pharmacy Summit in Las Vegas this week to give some insight on where we are with cell and gene therapies, as well as looking at Pfizer's discontinued hemophilia B gene therapy, Beqvez (fidanacogene elaparvovec-dzkt).
A future where healthcare may include augmented reality, robots and drones may be more fact than fiction, says George Van Antwerp, SVP of product innovation and strategic planning at Prime Therapeutics.
As healthcare AI evolves, there will be a greater emphasis on streamlining administrative tasks, drug production and service delivery, according to George Van Antwerp, SVP of product innovation and strategic planning at Prime Therapeutics.
Shawn Griffin, M.D., president and CEO of URAC, shared his insights into best practices for promoting health equity during the annual Asembia Specialty Pharmacy Summit in Las Vegas today.
At this year’s Asembia conference in Las Vegas, Shawn Griffin, M.D., president and CEO of URAC, spoke about the need for strong leadership and community-based data in specialty pharmacies to identify and address health disparities, which will then improve care for all patients.
Managed Healthcare Executive asked several experts in healthcare and managed care to share the trends they think the industry is overlooking. From rising costs and data challenges to shifts in how care is delivered, these are the issues that could have a major impact — and deserve a closer look.
Patients and providers found common ground on the importance of correct billing estimates but did not see eye to eye in terms of digital scheduling tool use, according to a new survey by Experian Health.
There is a lack of agreement on the clinical, psychological and social relevance of menopause between the transgender and gender diverse communities and medical professionals, according to the results of a study published this month in Menopause.
Researchers of a new JAMA study said that without further participation in accountable care organizations, including the ACO REACH model, the program is unlikely to meet its goal of reducing health disparities.
CVS Health released a statement shortly after HB1150 was signed in Arkansas, prohibiting pharmacy benefit managers from owning pharmacies.
In a recent conversation with Managed Healthcare Executive, Geoffrey Rutledge, M.D., of HealthTap, warned that the narrative around GLP-1 drugs is often oversimplified—and potentially harmful.
On lobbying, hospitals, PBM reform and 340B
On lobbying, the political power of hospitals, PBM reform and 340B
Women who undergo menopause before the age of 40 are more likely to experience cognitive decline, which may lead to dementia, according to new research.
Here’s what you missed this week on Managed Healthcare Executive.
Maureen Corcoran, director of the Ohio Department of Medicaid, believes the work requirement policy can be both a financial and moral effort to improve the lives of Medicaid consumers.
Medicaid is the main healthcare coverage for people living with HIV in the United States, according to data compiled by KFF.
With policymakers considering work requirements for Medicaid eligibility, Jennifer Haley, principal research associate in the Health Policy Division at the Urban Institute, said it’s more important than ever to understand how those changes could unintentionally cause harm, particularly when data systems fall short and public awareness is limited.
